- Home
- UTHR
as 11-20-2024 4:00pm EST
United Therapeutics specializes in drug development for pulmonary arterial hypertension, a rare and progressive disease marked by abnormally high blood pressure in the arteries of the lungs. The company's therapies for PAH largely focus on the prostacyclin pathway, and many of its treatments are based on the same molecule, treprostinil. Most of the company's sales are generated within the United States. United Therapeutics also markets a pediatric oncology drug, but its focus largely remains in pulmonary arterial hypertension.
| Founded: | 1996 | Country: | United States |
| Employees: | N/A | City: | SILVER SPRING |
| Market Cap: | 15.5B | IPO Year: | 1999 |
| Target Price: | $370.86 | AVG Volume (30 days): | 371.2K |
| Analyst Decision: | Buy | Number of Analysts: | 14 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | 22.72 | EPS Growth: | 25.10 |
| 52 Week Low/High: | $208.62 - $417.82 | Next Earning Date: | 10-30-2024 |
| Revenue: | $2,756,200,000 | Revenue Growth: | 25.04% |
| Revenue Growth (this year): | 26.32% | Revenue Growth (next year): | 10.37% |
Stock Insider Trading Activity of United Therapeutics Corporation (UTHR)
| Name | Ticker | Relationship | Date | Transaction | AVG Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Nov 11 '24 | Sell | $407.67 | 15,000 | $6,109,840.99 | 0 | |
| Mesa Nilda | UTHR | Director | Nov 8 '24 | Sell | $412.28 | 224 | $92,350.27 | 5,783 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Nov 6 '24 | Sell | $397.31 | 25,000 | $9,971,214.12 | 0 | |
| Giltner Richard | UTHR | Director | Nov 5 '24 | Sell | $381.94 | 10,000 | $3,817,022.00 | 18,849 | |
| EDGEMOND JAMES | UTHR | CFO AND TREASURER | Nov 4 '24 | Sell | $374.02 | 7,778 | $2,909,127.56 | 7,512 | |
| CAUSEY CHRISTOPHER | UTHR | Director | Nov 1 '24 | Sell | $376.63 | 510 | $192,080.33 | 3,675 | |
| BENKOWITZ MICHAEL | UTHR | PRESIDENT AND COO | Nov 1 '24 | Sell | $374.41 | 14,700 | $5,504,605.09 | 0 | |
| EDGEMOND JAMES | UTHR | CFO AND TREASURER | Oct 28 '24 | Sell | $350.00 | 7,800 | $2,730,000.00 | 7,512 | |
| EDGEMOND JAMES | UTHR | CFO AND TREASURER | Oct 21 '24 | Sell | $366.99 | 7,782 | $2,855,916.18 | 7,512 | |
| EDGEMOND JAMES | UTHR | CFO AND TREASURER | Oct 14 '24 | Sell | $355.88 | 7,792 | $2,773,016.96 | 7,512 |
Latest United Therapeutics Corporation News
UTHR Breaking Stock News: Dive into UTHR Ticker-Specific Updates for Smart Investing
Zacks
21 hours ago
Why This 1 Value Stock Could Be a Great Addition to Your Portfolio
Business Wire
16 days ago
United Therapeutics Corporation to Present at the UBS Global Healthcare Conference
Zacks
16 days ago
United Therapeutics (UTHR) is a Top-Ranked Growth Stock: Should You Buy?
Zacks
17 days ago
United Therapeutics (UTHR) is a Top-Ranked Value Stock: Should You Buy?
Zacks
20 days ago
United Therapeutics Q3 Earnings & Sales Beat Estimates
Morningstar Research
21 days ago
Analyst Report: United Therapeutics Corporation
Argus Research
21 days ago
Analyst Report: United Therapeutics Corp
Argus Research
21 days ago
Market Digest: ADP, LLY, MCD, UTHR, WM, SMCI, HCA, QRVO, SNAP
Compare UTHR vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "UTHR United Therapeutics Corporation - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.